Browsing Tag
Elahere
6 posts
Zymeworks (ZYME) reports 64.5% ovarian cancer response rate for ZW191 as lower dose strengthens case
Zymeworks has reported encouraging Phase 1 results for its folate receptor alpha-targeting antibody-drug conjugate ZW191, including responses in ovarian tumors with low receptor expression and a more favorable safety profile at the lower tested dose.
AbbVie’s bold gamble: Can Elahere really launch in the UK at full U.S. list price?
AbbVie plans to launch ovarian cancer drug Elahere in UK at U.S. price—testing NICE, NHS, and investor confidence in oncology pricing norms.
AbbVie’s ELAHERE demonstrates 32% reduction in death risk for ovarian cancer patients
A final analysis of the Phase 3 MIRASOL trial has confirmed that ELAHERE (mirvetuximab soravtansine-gynx) provides a significant…
FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food…
AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical…
ImmunoGen secures up to $175m from Pharmakon Advisors to accelerate oncology growth
ImmunoGen secures up to $175M in non-dilutive funding from Pharmakon to fuel Elahere’s launch and expand its next-gen ADC pipeline. Read the full breakdown.